UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO(TM), Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer
Stock Information for OncoSec Medical Incorporated
Loading
Please wait while we load your information from QuoteMedia.